UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                       WASHINGTON, D.C.  20549
                              FORM 10-Q


      [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                 OF THE SECURITIES EXCHANGE ACT OF 1934

            For the quarterly period ended December 31, 1993

                                OR

      [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                OR THE SECURITIES EXCHANGE ACT OF 1934
         For the transition period from          to         

                  Commission file number 1-9114

                      MYLAN LABORATORIES INC.
     (Exact Name of registrant as specified in its charter)

     Pennsylvania                            25-1211621
(State or other jurisdiction of           (I.R.S. Employer    
incorporation or organization)            Identification No.)

          130 Seventh Street
         1030 Century Building
        Pittsburgh, Pennsylvania                    15222
   (Address of principal executive offices)       (Zip Code)

                          412-232-0100
     (Registrant's telephone number, including area code)

                         Not Applicable
  (Former name, former address and former fiscal year, if changed
   since last report)

Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding twelve
months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:

               YES   X             NO      

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date

                                             Outstanding at
          Class of Common Stock              January 21, 1994
               $.50 par value                   79,149,950




           MYLAN LABORATORIES INC. AND SUBSIDIARIES


                            INDEX




                                                         Page
                                                        Number



PART I. FINANCIAL INFORMATION

Consolidated Balance Sheets - December 31, 1993
   and March 31, 1993                                   2A and 2B

Consolidated Statements of Earnings - Three and
   Nine Months Ended December 31, 1993 and 1992              3

Consolidated Statements of Cash Flows - Nine
   Months Ended December 31, 1993 and 1992                   4

Notes to Consolidated Financial Statements -

   Three and Nine Months Ended December 31, 1993       5, 6 and 7

Management's Discussion and Analysis of
   Financial Condition and Results of
   Operations                                             8 and 9



PART II. OTHER INFORMATION                                  10

<PAGE>


           MYLAN LABORATORIES INC. AND SUBSIDIARIES
                  CONSOLIDATED BALANCE SHEETS
                            ASSETS




                                        December 31,    March 31,
                                           1993           1993 
                                         Unaudited      Audited

Current Assets
  Cash and cash equivalents             $103,021,000 $ 98,246,000

  Accounts receivable                     48,774,000   32,396,000

   Inventories:
     Raw materials                        25,316,000   23,115,000

     Work in process                      12,153,000   11,553,000

     Finished goods                       17,262,000   11,281,000
                                          54,731,000   45,949,000

  Deferred tax benefit
  Other current assets                     1,284,000        -
                                           7,090,000    3,891,000

     Total Current Assets                214,900,000  180,482,000

Property, Plant and Equipment - at cost  106,160,000   94,950,000
     Less accumulated depreciation        30,929,000   26,431,000
                                          75,231,000   68,519,000

Investment in and Advances to Somerset    17,827,000   14,844,000

Intangible Assets 
net of accumulated amortization           34,448,000   38,115,000

Other Assets                              51,240,000   49,145,000

Total Assets                            $393,646,000 $351,105,000






       See Notes to Consolidated Financial Statements

                           -2A-
<PAGE>
   
              LIABILITIES AND SHAREH0LDERS' EQUITY


[CAPTION]
                                        December 31,   March 31,
                                            1993         1993 
                                         Unaudited     Audited   


Current Liabilities
   Trade accounts payable              $  5,686,000  $  6,492,000

     Income taxes payable                 2,242,000     9,349,000

     Other current liabilities           12,783,000     8,293,000

     Cash dividend payable                3,168,000     2,348,000

         Total Current Liabilities       23,879,000    26,482,000

Acquisition Obligation                         -       21,303,000

Long-Term Obligations                     4,363,000     5,125,000

Deferred Income Taxes                       271,000     2,223,000

Shareholders' Equity:
  Preferred stock, par value $.50 per
  share, authorized 5,000,000 shares,           -         -
  issued and outstanding - none


  Common stock, par value $.50 per share,
  authorized 300,000,000 shares, issued
  79,624,339 shares at December 31, 1993
  78,615,453 shares at March 31, 1993    39,812,000    39,309,000

  Additional paid in capital             53,699,000    29,866,000

  Retained earnings                     274,131,000   227,139,000
                                        367,642,000   296,314,000
  Less Treasury stock - at cost, 495,864                          
  shares at December 31, 1993 and 430,206
  shares at March 31, 1993                2,509,000       342,000
Net Worth                               365,133,000   295,972,000

Total Liabilities and 
    Shareholders' Equity               $393,646,000  $351,105,000


              

             See Notes to Consolidated Financial Statements 
                                -2B-                     
                            MYLAN LABORATORIES INC. AND SUBSIDIARIES
                               CONSOLIDATED STATEMENTS OF EARNINGS
                                           UNAUDITED

<TABLE>
<CAPTION>
                            Three Months Ended December 31,  Nine Months Ended December 31,
                                 1993             1992                1993          1992
<S>                           <C>             <C>             <C >            <C>                       
NET SALES                     $ 66,436,000    $ 61,108,000    $182,699,000    $150,966,000
COST AND EXPENSES:
  Cost of Sales                 32,165,000      24,489,000      90,628,000      64,920,000 
    Research and Development     5,499,000       3,804,000      16,453,000      10,123,000

  Selling and Administrative    14,284,000      10,681,000      36,745,000      26,920,000

     Interest Expense                8,000           8,000          23,000          26,000
                                51,956,000      38,982,000     143,849,000     101,989,000
EQUITY IN EARNINGS OF SOMERSET   6,841,000       6,120,000      18,250,000      15,530,000

OTHER INCOME                     4,634,000       1,423,000       7,481,000       2,479,000

EARNINGS BEFORE INCOME TAXES    25,955,000      29,669,000      64,581,000      66,986,000

INCOME TAX RATE                     15%              29%            14%              26%

INCOME TAXES                     3,832,000       8,494,000       8,908,000      17,751,000

NET EARNINGS                  $ 22,123,000    $ 21,175,000    $ 55,673,000    $ 49,235,000
EARNINGS PER SHARE            $        .28    $        .28    $        .71    $        .64

WEIGHTED AVERAGE COMMON SHARES  79,091,000      76,974,000      78,876,000      76,902,000

The Company paid regular quarterly cash dividends of $.025 per share from July 1990 to
July 1992, $.03 per share from October 1992 to July 1993 and $.04 per share on October 15,
1993 and January 15, 1994.
</TABLE>
                     
                          See Notes to Consolidated Financial Statements
                                                       -3-               


               MYLAN LABORATORIES INC. AND SUBSIDIARIES
                 CONSOLIDATED STATEMENTS OF CASH FLOWS
       FOR THE NINE MONTHS ENDED DECEMBER 31, 1993 AND 1992

                               UNAUDITED
[CAPTION]
                                            1993        1992

CASH FLOWS FROM OPERATING ACTIVITIES
 Net Earnings                          $ 55,673,000 $ 49,235,000 
 Adjustments to reconcile net earnings 
  to net cash from operating activities: 
    Depreciation and amortization         8,232,000    3,713,000
    Deferred income taxes                  (434,000)    (100,000)
    Equity in the earnings of Somerset  (18,250,000) (15,530,000) 
    Cash received from Somerset          15,267,000   13,988,000 
    Other non-cash expenses               8,113,000    5,887,000
  Changes in operating 
          assets and liabilities:
    Accounts receivable                 (21,064,000) (11,091,000)
    Inventories                          (8,737,000)  (7,811,000)
    Trade accounts payable                 (806,000)     (27,000)
    Income taxes payable                 (8,869,000)   2,560,000
    Other operating 
    assets and liabilities               (3,869,000)   3,726,000
NEt cash provided from 
          operating activities           25,256,000   44,550,000 
CASH FLOWS FROM INVESTING ACTIVITIES
 Additions to property, 
 plant and equipment                    (11,210,000)  (7,509,000) 
 Increase in other assets                (1,214,000) (10,977,000)
Net cash used in investing activities   (12,424,000) (18,486,000)

CASH FLOWS FROM FINANCING ACTIVITIES
 Cash dividend paid                      (7,861,000)  (6,152,000)
 Payments on long-term debt                 (14,000)     (50,000)
 Payments on acquisition obligations       (977,000)        - 
 Proceeds from exercise of stock options    795,000    9,208,000
Net cash provided from (used in) 
 financing activities                    (8,057,000)   3,006,000
Net Increase in Cash 
        and Cash Equivalents              4,775,000   29,070,000 
Cash and Cash Equivalents - 
     Beginning of Period                 98,246,000   60,324,000 
Cash and Cash Equivalents - 
 End of Period                         $103,021,000 $ 89,394,000 
CASH PAID DURING THE PERIOD FOR:
 Interest                              $     23,000 $     23,000
 Income Taxes                          $ 11,417,000 $ 15,234,000



              See Notes to Consolidated Financial Statements
                                -4-
           MYLAN LABORATORIES INC. AND SUBSIDIARIES
          NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
               THREE AND NINE MONTH PERIOD ENDED
                        DECEMBER 31, 1993

                             Unaudited

A.  On November 5, 1993 Roy McKnight, Chairman and Chief
    Executive Officer of the Company since 1976, suffered a fatal
    heart attack.  Mr. McKnight passed away the following day. 
    On November 9, 1993 Milan Puskar was named Chairman and       
    C.E.O. in addition to his existing position as President of   
    the Company.  Also, C.B. Todd, President of the Company's     
    wholly owned subsidiary Mylan Pharmaceuticals Inc., was       
    appointed to the Board of Directors of the Company.
    The Company has certain obligations to the estate and/or
    family of Mr. McKnight pursuant to a 1990 salary continuation
    agreement.  A one time charge against earnings of
    approximately $2.8 million is included in Selling and
    Administrative expenses in the quarter ended December 31,
    1993 relating to these obligations.  At December 31, 1993
    other accrued liabilities includes a total of $4,306,000
    which has been accrued by the Company for this obligation.

B.  On November 24, 1993 the Company reached a settlement with
    Pharmaceuticals Resources, Inc./Par Pharmaceuticals/Quad
    Pharmaceuticals, three defendants in the Company's suit filed
    under the Federal Antitrust Laws and the Racketeer Influenced
    and Corrupt Organization Act (RICO), against several
    pharmaceutical companies, certain employees of those
    Companies and certain former employees of the FDA Generic
    Drug Division.  Under the settlement, Pharmaceutical
    Resources, Inc. agreed to pay the Company the sum of
    $1,000,000 in cash and $2,000,000 in their common stock. 
    This settlement is reflected under the caption "Other Income"
    for the quarter ended December 31, 1993.

C.  On February 25, 1993, a wholly owned subsidiary of the
    Company acquired substantially all of the net assets of
    Bertek Inc. (Bertek) for approximately $39,112,000 and
    assumed liabilities of approximately $10,090,000.  The
    business combination has been accounted for under the
    purchase method of accounting.  Goodwill of approximately
    $2,686,000 resulting from the acquisition is being amortized
    on a straight-line basis over a 20 year period.
    To facilitate the transaction the Company issued 1,349,975
    shares of its common stock and paid cash of $9,375,000
    including approximately $8,293,000 paid by the Company at
    closing to satisfy certain long-term obligations assumed.  




                                    -5-
<PAGE>
 
         MYLAN LABORATORIES INC. AND SUBSIDIARIES
         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                        (Continued)


D.  Effective April 1, 1993 the Company adopted Statement of
    Financial Accounting Standards (SFAS) No. 109 "Accounting for
    Income Taxes".  Prior years financial statements were not
    restated.  The cumulative effect of adopting this standard
    resulted in an increase in net earnings of $1,124,000 ($.01
    per share) for the three months ended June 30, 1993.  There
    was no cash flow impact.  Expanded disclosure regarding the
    impact of the adoption of SFAS 109 was provided in the Report
    on Form 10-Q for the quarter ended June 30, 1993.

    SFAS 109 requires an asset and liability approach to
    accounting for income taxes.  Deferred tax assets and
    liabilities reflect the future tax consequences of events
    that have already been recognized in the financial statements
    or tax returns.  Changes in enacted tax rates or laws will
    result in adjustments to the recorded tax asset or
    liabilities in the period that the tax law is enacted.

    In August of 1993, President Clinton signed into law the
    Omnibus Budget Reconciliation Act of 1993 ("the Act").  The
    Act has several provisions which effect the Company's income
    tax expense including a change in the Federal corporate tax
    rate and significant changes relating to tax credits for
    operations in Puerto Rico.  As a direct result of the changes
    in the tax code, the Company reassessed its position on the
    filing alternatives available under the tax code.  Based on
    the new tax code provisions, the Company made a decision
    which resulted in a reduction of income tax expense of
    $3,225,000.  This amount represents management's estimate of
    the cumulative effect of this change.

E.  In the opinion of management, the accompanying unaudited
    financial statements contain all adjustments (consisting of
    only normal recurring accruals) necessary to present fairly
    the financial position of the Company as of December 31, 1993
    and March 31, 1993 together with the results of operations
    and cash flows for the interim periods ended December 31,
    1993 and 1992.  The consolidated results of operations for
    the three and nine months ended December 31, 1993 and 1992
    are not necessarily indicative of the results to be expected
    for the full year. These interim financial statements should
    be read in conjunction with the consolidated financial
    statements and notes thereto in the Company's 1993 Annual
    Report.



                                    -6-
<PAGE>
       
            MYLAN LABORATORIES INC. AND SUBSIDIARIES
           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                           (Continued)


F.  Equity in Earnings of Somerset includes the Company's 50%
    portion of the net earnings of Somerset Pharmaceuticals Inc.
    (Somerset), certain management fees and amortization of
    intangible assets resulting from the acquisition of Somerset. 
    Such intangible assets are being amortized over a 15 year
    period using the straight line method.

    Condensed unaudited financial information of Somerset for the
    three and nine month periods ended December 31, 1993 and 1992
    are as follows: (in thousands)







                       Three Months Ended       Nine Months Ended
                        December 31,               December 31,
                      1993     1992             1993      1992


 Net Sales           $36,422  $32,538          $88,107   $77,628

Costs and Expenses   (19,470) (15,687)         (40,789)  (34,840)

Income Taxes          (5,070) ( 6,236)         (15,220)  (15,601)

Net Earnings         $11,882  $10,615          $32,098   $27,187


    The above information represents 100% of Somerset's
    operations of which the Company has a 50% interest.













                                    -7-


 
               PART 1 - FINANCIAL INFORMATION


         ITEM 2 - MANAGEMENTS DISCUSSION AND ANALYSIS
       OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Results of Operations

  Net sales for the three months ended December 31, 1993 were a
record high $66,436,000 exceeding the previous record high
quarterly sales for the same quarter a year ago by 9%.  For the
nine month period ended December 31, 1993 net sales were
$182,699,000 representing a 21% increase over the same period a
year ago.  Sales of five new generic products added to the
Company's product line in December and an overall increase in
generic volume, up 15% quarter to quarter and 25% year to date,
along with sales revenues from Bertek which was acquired in
February 1993, have helped to offset significant price erosion
which continues to effect products added to the generic line
during the last fiscal year.

  As a direct result of significant pricing competition in the
generic markets and the addition of Bertek revenues, which
generally provide lower gross margin rates, gross margin as a
percent of sales has decreased from 60% for the December 1992
quarter to 52% this year and from 57% for the nine months ended
December 1992 to 50% this year.

  Indicative of the Company's commitment to new and increased
product development to broaden the Company's product line,
current year expenditures for research and development have
increased significantly over prior years.  This increase is due
to research projects throughout the Company.

  As discussed in footnote A, Selling and Administrative expenses
for the quarter ended December 31, 1993 includes a charge of
$2,800,000 for obligations pursuant to a salary continuation
agreement for Mr. McKnight.  Excluding this one time charge,
Selling and Administrative expenses were 17% of net sales for the
quarters ended December 31, 1993 and 1992 and were 19% of sales
for the nine month period ended December 31, 1993 versus 18% last
year.  Amortization of intangible assets associated with the
Bertek acquisition of approximately $3,000,000 are included in
the 1993 year to date amount.  Other factors contributing to the
increase include advertising and promotion expenses associated
with new products and legal and professional fees associated with
the various court actions to which the Company is a party.

  Equity in earnings of Somerset continues to provide a solid
return for the Company.  Somerset's contribution to net earnings
per share for the three and nine month periods was $.08 and $.21
in 1993 and $.07 and $.18 in 1992.

                                    -8-
<PAGE>


  Effective April 1, 1993 the Company adopted Statement of
Financial Accounting Standards (SFAS) No. 109 "Accounting for
Income Taxes" which resulted in a reduction of income tax expense
and a corresponding increase in net earnings during the quarter
ended June 30, 1993 of $1,124,000 or $.01 per share.

  During the quarter ended September 30, 1993, as a direct result
of changes in the Federal Tax Code enacted in August of 1993, the
Company reassessed its position on the filing alternatives
available under the tax code.  Based on the new tax code
provision the Company made a decision which resulted in a
reduction of income tax expense of $3,225,000.  Excluding the
effects of adoption of FAS 109 and the management decision
predicated on the changes in the tax code, the effective tax rate
for the nine months ended December 31, 1993 is roughly 21%
compared to 25% for the same period a year ago.  This decrease is
due to higher levels of production at the Company's Puerto Rico
facility.


Liquidity and Capital Resources and Financial Condition

  Working capital increased from $154,000,000 at March 31, 1993
to $191,021,000 at December 31, 1993 as a result of continued
strong operations.  The ratio of current assets to current
liabilities was 6.8 to 1 at March 31, 1993 and 9.0 to 1 at
December 31, 1993.

  Cash flows from operating activities remain strong but have
decreased from the prior year due principally to the timing of
new product sales and increased levels of operating expenditures
and inventory purchases.

  Additions to property, plant and equipment amounted to
$11,210,000 in the current year including construction projects
at the Company's West Virginia and Puerto Rico facilities and new
projects at the Bertek facility in Vermont.













                                    -9-
<PAGE>
    

 
             PART II. OTHER INFORMATION



  Item 1. Legal Proceedings

      On November 24, 1993 the Company reached a settlement with
Pharmaceuticals Resources, Inc./Par Pharmaceuticals/Quad
Pharmaceuticals, three defendants in the Company's suit filed
under the Federal Antitrust Laws and the Racketeer Influenced and
Corrupt Organization Act (RICO), against several pharmaceutical
companies, certain employees of those Companies and certain
former employees of the FDA Generic Drug Division.  Under the
settlement, Pharmaceutical Resources, Inc. agreed to pay the
Company the sum of $1,000,000 in cash and $2,000,000 in their
common stock.



  Item 6. Exhibits and Reports on Form 8-K
  (b) Reports on Form 8-K - On November 15, 1993 the Company
filed a report on Form 8-K dated November 6, 1993 covering Item 5
thereof regarding the death of Roy McKnight and the appointments
of Milan Puskar as Chairman and Chief Executive Officer and C.B.
Todd as a member of the board of directors.


                           UNITED STATES                          
                SECURITIES AND EXCHANGE COMMISSION
                       WASHINGTON, D.C. 20549
                                    
                                    
                              Form 8-K
                                    
                           Current Report
                                    
                 Pursuant to Section 13 or 15(d) of
                      The Securities Act of 1934
                                    
                                    
                                    
Date of Report (Date of earliest event reported)  November 6,1993




                       MYLAN LABORATORIES INC.
        (Exact name of registrant as specified in its charter)








Pennsylvania                  1-9114              25-1211621
(State or other           (Commission          (I.R.S. Employer
jurisdiction of           File Number)       Identification No.)
incorporation)








                       130 Seventh Street
                      1030 Century Building                       
                       Pittsburgh, PA 15222
              (Address of principal executive offices)

              
              
              
              
Registrant's telephone number, including area code (412) 232-0100











Item 5. Other Events.

     On November 9, 1993, the board of directors of Mylan
Laboratories Inc.(the "Registrant") named Milan Puskar, age 59,
as its Chairman and Chief Executive Officer, in addition to his
current position as President, and named C.B. Todd as a member of
its board of directors.  Mr. Puskar succeeds Roy McKnight, who
was stricken by a fatal heart attack the previous weekend, and
Mr. Todd's election fills the resulting vacancy on the board. Mr.
Todd, age 59, is a Senior Vice President of the Registrant, a
member of its Executive Committee and President of Mylan
Pharmaceuticals, Inc., a wholly-owned subsidiary of the
Registrant. He has served in various positions with the
Registrant since 1970.





Signature


Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.


                                MYLAN LABORATORIES INC.


                               By:  /S/  Milan Puskar                        
                                    Milan Puskar, Chairman,
                                    Chief Executive Officer and
                                    President


Date:   November 12,1993
        Pittsburgh, Pennsylvania





                                  SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.

                                        Mylan Laboratories Inc.
                                             (Registrant)



DATE                     /S/ Milan Puskar        2/3/94               
  
                             Milan Puskar
                             Chairman, President & C.E.O.



DATE                     /S/ Frank A. DeGeorge   2/3/94                    
  
                             Frank A. DeGeorge
                             Director of Accounting and Taxation





                                     -10-